Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ly-3009120, belvarafenib, tovorafenib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 1,342 | 0.91 |
| pathways Reactome | 11 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 3864
Sealed predictions
- ARAF in dopamine neurons, braak-0.41 (p 0.276) → -0.20 (p 0.613)receipt 3871
Swarm cases
receipt 3871: ARAF in dopamine neurons, braak
- power
- full sample -0.24 (p 0.346, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.424, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.221, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.13, sign flips 0; without severely affected donors -0.24 (p 0.346, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARAF in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts